Lupin gets USFDA approval for Formoterol Fumarate Inhalation Solution

The company has received approval from the USFA for the product which is a generic version of Mylan Specialty's Perforomist Inhalation Solution, the Mumbai-based drug maker said in a statement

Lupin
As per IQVIA MAT June 2022 data, the medication had annual sales of around USD 282 million in the US market.
Press Trust of India New Delhi
1 min read Last Updated : Aug 24 2022 | 9:34 PM IST

Lupin on Wednesday said it has received approval from the USFDA for Formoterol Fumarate Inhalation Solution, used in treating symptoms of chronic obstructive pulmonary disease.

The company has received approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Mylan Specialty's Perforomist Inhalation Solution, the Mumbai-based drug maker said in a statement.

As per IQVIA MAT June 2022 data, the medication had annual sales of around USD 282 million in the US market.

Shares of Lupin ended 2.55 per cent down at Rs 677.65 apiece on the BSE on Wednesday.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :LupinUSFDAgeneric medicines

First Published: Aug 24 2022 | 9:34 PM IST

Next Story